

Drug Utilization in Neonatal Intensive Care Unit of a Tertiary-care Hospital in Mumbai, India

SHAILESH ATMARAM CHAUTHANKAR, PADMAJA ANIL MARATHE, ANIRUDHA VYANKATESH POTEY AND

*RUCHI NIMISH NANAVATI

From Departments of Pharmacology and Therapeutics and *Neonatology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India.

Correspondence to:

Dr Padmaja Anil Marathe,
Department of Pharmacology and
Therapeutics, Seth GS Medical
College and KEM Hospital, Mumbai,
Maharashtra 400 012, India,
pam2671@gmail.com

Received: September 22, 2016;

Initial Review: April 07, 2017;

Accepted: July 24, 2017.

Objective: To study the prescription pattern (using applicable WHO indicators), cost analysis and off-label use of drugs in neonatal intensive care unit (NICU) of a tertiary-care hospital. **Methods:** The prescriptions of 460 neonates admitted to a NICU during July 2014-March 2015 were studied prospectively. **Results:** Of 460 neonates, 54.8% were preterm and 73% were low birth weight (LBW). The mean (SD) prescription items per neonate were 5.7 (3.6). Overall off-label use was 12.3%, while 38% neonates received at least one off-label drug. Of 326 off-label drugs, antibiotics (69.6%) followed by non-steroid anti-inflammatory drugs (7%) were commonly used. Premature and LBW babies required more drugs with higher cost and longer stay, compared to full term and normal weight babies ($P < 0.01$), while the pattern of off-label use was similar across both these categories ($P > 0.05$). **Conclusion:** Off-label antibiotics use was common, and prescribing practices were uniform in NICU.

Keywords: Audit, Antibiotic, Cost analysis, Prescriptions.

Published online: August 24, 2017. PII: S097475591600084

Evidence of safety and efficacy of drugs in adults is often extrapolated to neonates without evidence of systematic studies in neonates [1,2]. Such practices often result in ineffective drug therapy, increased use of off-label drugs, wastage of resources, increased mortality and morbidity, adverse events and cost of the treatment. We studied prescription pattern, cost and off-label use in neonatal intensive care unit (NICU) of a tertiary-care hospital.

METHODS

This descriptive study was conducted in a NICU of a tertiary-care hospital, Mumbai, India over a period of 9 months (July 2014 to March 2015). Institutional Ethics Committee approval was obtained. Neonates admitted to NICU and receiving at least one drug were recruited after written informed consent from a parent/guardian. Neonates only under observation or not receiving any medications other than blood and blood products, vitamin K prophylaxis, prophylactic ophthalmic treatment, vaccines or intravenous fluids were excluded. Demographic details were noted. Various drugs prescribed, total (direct and indirect) cost, off-label use of drugs, availability of drugs on hospital schedule, duration of hospital stay and outcome of treatment (survived/dead) were noted at the time of discharge or death.

For purpose of prescription analysis, individual drug prescribed to each neonate was considered as a 'prescription item' irrespective of total duration of its administration [3].

Off-label status of the drug was determined by referring to British National Formulary for Children (2011-2012) and Neofax (2011) whenever there was any deviation in prescribing drugs with respect to indication, dose, dosage forms, frequency of administration, and age [4,5]. Costs were calculated from patients' perspective (in Indian Rupees (INR), 1 US Dollar = 62.4 INR as on 31st March 2015). Expenses incurred due to investigations conducted outside the hospital or drugs purchased from outside and cost of travel were included in the direct cost. Loss of wages of attending parents/guardians during period of neonatal hospitalization were considered as indirect costs [6,7].

Statistical analysis: Data were analyzed using SPSS version 21. Non-parametric data between groups were compared using Mann-Whitney U test. P value < 0.05 was considered significant.

RESULTS

Out of 1080 neonates screened, 460 were included in the study, while 620 were excluded as they received no medications and were managed by other supportive measures. Mean (SD) birth weight was 2 (0.7) kg (range

0.7 kg to 3.8 kg). Median (range) age at the time of hospitalization and length of hospital stay were 1 (1, 27) day and 10 (2, 78) days, respectively. Among neonates, 59.3% were males, 54.8% were preterm, 42.8% had low birth weight and 81.1% were from lower middle and lower socioeconomic class [8]. Common clinical conditions were respiratory distress, sepsis and pneumonia, followed by meconium aspiration, neonatal seizures, and congenital heart diseases. A total of 392 (85.2%) neonates were admitted within first few hours after birth while 421 (91.5%) were admitted during the first week of their life; 417 (90.7%) neonates survived and were discharged.

Prescription pattern analysis is described in **Table I**. 'Injection' was the most commonly used dosage form (61.9%) followed by drops (23.3%) and syrups (13.4%). Amikacin (35.8%), meropenem (10.1%) and dobutamine (7.7%) were most commonly prescribed generic drugs, while multivitamins (20.7%), ampicillin+sulbactam (19.9%) and calcium with phosphorus (17%) were most commonly prescribed by brand names. Drugs unavailable on hospital schedule and purchased from market constituted 41.3%, of which multivitamins syrup (30.7%) was most commonly prescribed followed by calcium with phosphorus (25.2%), iron (17.9%) and caffeine (13.4%).

Of 460 neonates, 374 (81.3%) received antibiotics. Among them, 215 (57.5%) received ampicillin-sulbactam with amikacin as first-line empirical therapy, as per departmental protocol. High-end antibiotics like carbapenems, piperacillin-tazobactam, colistin,

linezolid, tigecycline were used in remaining cases (42.5%), while 18.7% of neonates did not receive any antibiotic.

Out of 2642 drugs used, 326 (12.3%) drugs were used off-label. About 175 (38%) neonates were prescribed at least one off-label drug ranging from 0-9 off-label drugs in one neonate. Most of the drugs were off-label for the 'dose' category (52%) followed by categories - 'age' (21%) and 'combined' (15%). No drug was used off-label for 'dosage form' and 'route'. Magnesium sulphate, administered for controlling seizures in neonates, was the only drug used off-label for 'indication'. Antibiotics were the most commonly prescribed off-label class of drugs accounting for 69.6%, followed by NSAIDs (7%) and steroids (3%). Among antibiotics, meropenem (31.7%) was most commonly prescribed off-label drug followed by piperacillin-tazobactam (19.8%) and ampicillin-sulbactam (14.5%). Among NSAIDs, paracetamol, and ibuprofen and among steroids, hydrocortisone were most commonly prescribed off-label drugs, respectively. Meropenem (39%) followed by piperacillin-tazobactam (24%) were most commonly prescribed off-label drugs in 'dose' category. Ampicillin-sulbactam (18%) and colistin (43%) were most commonly used as off-label as per 'frequency' of administration and 'age', respectively. In 'combined' category, meropenem (98%) was most commonly used, which was off-label for dose as well as for frequency.

The average cost of hospitalization per neonate was 7383 INR (median 4925 INR) of which direct cost was 2609 INR and indirect cost was 4774 INR. Minimum and maximum total cost of hospitalization were 60 INR and 60880 INR, respectively. Mean (SD) medical cost per neonate was 1411 (1341) INR while the average total cost of hospitalization per day was 545 INR.

Preterm (<37 weeks) and low birth weight (<2.5 kg) neonates were exposed to significantly higher number of drugs, had longer hospital stay with overall cost of treatment compared to full term neonates ($P < 0.05$), while number and pattern of off-label drug use was similar across all neonates irrespective of gestational age and birthweight ($P < 0.05$) (**Table II**).

DISCUSSION

In the present study, injections and antibiotics were the most common dosage form and class of drug used in neonates, respectively. Use of one or more off-label drugs was seen in 38% of neonates, and 'antibiotics' was the most common class for off-label use. The number of drugs, duration of hospital stay and cost was higher in preterm and low birth weight neonates.

TABLE I PRESCRIPTION PATTERN ANALYSIS (WHO/INRUD INDICATORS) OF DRUGS IN NICU

WHO Indicators	Results
Total number of prescription items	2642
Average number of drugs per neonate	5.7
Drugs prescribed by generic name (%)	38.8
Prescriptions with antibiotics (%)	40.8
Prescriptions with injections (%)	61.9
Drugs prescribed from hospital schedule (%)	58.7
Days per hospital admission (mean)	13.5
Drugs per inpatient-day (mean)	0.4
Antibiotics per inpatient-day (mean)	0.2
Injections per inpatient-day (mean)	0.3
Drug cost per inpatient-day (in INR) (mean)	15

WHO/INRUD- World health organization / International network for rational use of drugs, INR – Indian Rupees.

TABLE II COMPARISON OF VARIOUS VARIABLES AMONG DIFFERENT AGE- AND WEIGHT-CATEGORIES

	According to gestational age on delivery			According to birth weight		
	Preterm	Term	P value	Low birth weight	Normal birth weight	P value
Total drug use	6.6 (3.8)	4.7 (3)	<0.01	6.1(3.7)	4.8 (3.1)	<0.01
Off-label drug use	0.7 (1.3)	0.6 (1.1)	0.311	0.7 (1.2)	0.6 (0.9)	0.877
Hospital stay (in d)	16.4 (13.7)	10.1 (8)	<0.01	14.9 (12.2)	9.9 (9.1)	<0.01
Cost of the treatment (INR)	9069 (9294)	5341(4752)	<0.01	7979(8363)	5770(5751)	0.002

Values in mean (SD); INR- Indian Rupees.

The study results should be interpreted in the light of following limitations. Direct costs excluded drugs and investigations which were free of cost from hospital under government funded scheme – Janani Shishu Suraksha Karyakram [9]. Parents had to bear minimum cost. Indirect costs did not include capital costs (buildings, medical equipment, beds) and recurrent cost (staff salary, telephone electricity and laundry bills etc), but considered costs incurred only by parents.

Prevalence of off-label use in neonates has been reported in the range of 26-62% [10-13]. In NICUs of Germany [10], Australia [11], Derby, UK [12], Portugal [13] and Ireland [14], at least one off-label drug was received by 70%, 80%, 90%, 69.7% and 76%, of neonates, respectively; and regulatory labels or summary of product characteristic were followed for determining off-label use. Category-wise, Carvalho, *et al.* [3] reported ampicillin as most commonly prescribed off-label drug in ‘dose’ and ‘frequency’ category while paracetamol as off-label for ‘age’. In a study by Jain, *et al.* [1] antibiotics, and anti-epileptics were off-label in ‘age’ and ‘dose’ categories. Differences in off-label drug use reported in different studies can be attributed to differences in neonatal conditions, duration of hospitalization, availability of drugs and different resource materials (formularies/ labels) referred to determine off-label status.

Prescribing drugs by generic names and from hospital schedule is recommended to reduce the cost of treatment and thereby to promote rational use of drugs. It is usual practice to initiate antibiotic therapy empirically considering the seriousness of illness. Differences across NICUs regarding antibiotic use, are affected by experience of the neonatologist with respective antibiotics, local microorganism susceptibility pattern and local availability of antibiotics. Good prescribing practices were observed in our study (over 50 % neonates on supportive therapy alone, one-fifth without antibiotics, and use of lower-end antibiotics) with survival rate of 91 %.

Considering dearth of controlled clinical trials due to lack of interest by pharmaceutical companies and ethical issues related to neonatal recruitment, neonatologists are compelled to use drugs in an off-label manner to provide maximum benefit from available drug therapies [15]. Often prescription of off-label drugs is based on data from medical literature like case reports and series, recommendations from experts or neonatology societies [2,16]. Hence, this practice may be considered acceptable and even necessary in absence of a suitable alternative or guidelines [17]. Clinical studies are required to validate off-label use of drugs used in neonatal practice.

Acknowledgments: Dr Amit Birajdar and Dr Sarita Dabba for their generous help.

Contributors: SAC and PAM: conceptualisation, data collection, data analysis, manuscript writing; AVP: data analysis and interpretation, data collection, article writing; RNN: protocol designing, providing expertise and significant contributions in the conduct of study and in the drafting of the article, interpretation of data analysis.

Funding: None; *Competing interest:* None stated.

REFERENCES

- Jain S, Saini SS, Chawla D, Kumar P, Dhir S. Off-label use of drugs in neonatal intensive care units. *Indian Pediatr.* 2014;51:644-6.
- Zheng Z, Yang M, Wu J. Ethical off-label drug use: Need for a rethink? *Indian Pediatr.* 2017;54:447-50
- Carvalho CG, Ribeiro MR, Bonilha MM, Fernandes Jr M, Procianoy RS, Silveira RC. Use of off-label and unlicensed drugs in the neonatal intensive care unit and its association with severity scores. *J Pediatr (Rio J).* 2012;88:465-70.
- BMJ Publishing Group, London. The British National Formulary for Children 2011-2012. Available from: http://www.sbp.com.br/pdfs/British_National_Formulary_for_Children_2011-2012.pdf. Accessed October 18, 2014.
- Thomson R. Neofax, 24th ed. Inc Montvale, NJ. Thomson Reuters/Physicians' Desk Reference; 2011.
- McIntyre D, Thiede M, Dahlgren G, Whitehead M. What are the economic consequences for households of illness and of paying for health care in low- and middle-income country contexts? *Soc Sci Med.* 2006;62:858-65.

WHAT THIS STUDY ADDS?

- Off-label drug use is common in NICU, and needs validation. Higher drug use is involved in treating preterm and low birth weight neonates.

- Leardini G, Salaffi F, Caporali R, Canesi B, Rovati L, Montanelli R. Italian group for study of the costs of arthritis- direct and indirect costs of osteoarthritis of the knee. *Clin Exp Rheumatol.* 2004;22:699-706.
- Ravi Kumar BP, Dudala SR, Rao SR. Kuppaswamy's Socio-Economic Status Scale - a revision of economic parameter for 2012. *Int J Res Dev Health.* 2013;1:2-4.
- Neogi SB, Malhotra S, Zodpey S, Mohan P. Assessment of special care newborn units in India. *J Health Popul Nutr.* 2011;29:500-9.
- Neubert A, Lukas K, Lies T, Dormann H, Brune K, Rascher W. Drug utilisation on a preterm and neonatal intensive care unit in Germany: a prospective, cohort-based analysis. *Eur J Clin Pharmacol.* 2010;66:87-95.
- O'Donnell CP, Stone RJ, Morley CJ. Unlicensed and off-label drug use in an Australian neonatal intensive care unit. *Pediatrics.* 2002;110:e52.
- Conroy S, McIntyre J, Choonara I. Unlicensed and off label drug use in neonates. *Arch Dis Child Fetal Neonatal Ed.* 1999;80:F142-5.
- Kumar P, Walker JK, Hurt KM, Bennett KM, Grosshans N, Fotis MA. Medication use in the neonatal intensive care unit: current patterns and off-label use of parenteral medications. *J Pediatr.* 2008;152:412-5.
- Kieran EA, O'Callaghan N, O'Donnell CP. Unlicensed and off-label drug use in an Irish neonatal intensive care unit: a prospective cohort study. *Acta Paediatrica.* 2013:e139- e142.
- Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder LS, Kauffman RE. Developmental pharmacology: Drug disposition, action, and therapy in infants and children. *N Engl J Med.* 2003;349:1157-67.
- Jain SS, Bavdekar SB, Gogtay NJ, Sadawarte PA. Off-label drug use in children. *Indian J Pediatr.* 2008;75:1133-6.
- Hill P. Off-licence and off-label prescribing in children: Litigation fears for physicians. *Arch Dis Child.* 2005;90:i17-8.